Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
Not Confirmed
Not Confirmed
07-09 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Industry Trade Show
Not Confirmed
07-09 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-s-landmark-approvals-of-bms-schizo-med-madrigal-s-mash-drug-us-16-5-bn-catalent-buyout-make-it-to-top-10-news-of-2024
30 Oct 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/quantum-leap-healthcare-collaborative-initiates-landmark-phase-2-recast-dcis-platform-trial-to-evaluate-alternative-dcis-treatments-with-atossa-therapeutics-havah-therapeutics-and-the-menarini-group-301971653.html
30 Mar 2023
// BUSINESSWIRE
20 Dec 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/12/20/2577055/0/en/Athenex-Announces-Quantum-Leap-Healthcare-Collaborative-Reports-Positive-Trial-Result-of-I-SPY2-Trial-for-Oral-Paclitaxel-in-Combination-with-PD-1-and-Carboplatin-in-Neoadjuvant-Br.html
16 Sep 2022
// CLINICALTRIALSARENA
https://www.clinicaltrialsarena.com/news/omeros-covid-trial-narsoplimab/
15 Sep 2022
// BUSINESSWIRE
15 Aug 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/08/15/2498064/0/en/ALX-Oncology-and-Quantum-Leap-Healthcare-Collaborative-Announce-the-Selection-of-Evorpacept-in-the-I-SPY-P1-TRIAL-in-Combination-with-Enhertu-in-Breast-Cancer.html
Details:
Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Brand Name: Endoxifen
Study Phase: Phase IIProduct Type: Small molecule
Recipient: Atossa Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Lead Product(s) : Endoxifen
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Atossa Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Brand Name : Endoxifen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 28, 2023
Details:
(Z)-endoxifen is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Recipient: Atossa Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Lead Product(s) : Endoxifen
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Atossa Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : (Z)-endoxifen is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 21, 2023
Details:
ALX148 (evorpacept), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is being investigated in combination with enhertu for breast cancer.
Lead Product(s): Evorpacept,Fam-trastuzumab Deruxtecan-nxki
Therapeutic Area: Oncology Brand Name: ALX148
Study Phase: Phase IProduct Type: Large molecule
Recipient: ALX Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Lead Product(s) : Evorpacept,Fam-trastuzumab Deruxtecan-nxki
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : ALX Oncology
Deal Size : Not Applicable
Deal Type : Not Applicable
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SP...
Details : ALX148 (evorpacept), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is being investigated in combination with enhertu for breast cancer.
Brand Name : ALX148
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 13, 2023
Details:
Oral paclitaxel, relative to intravenous paclitaxel, was associated with less neuropathy and was not associated with an increase in febrile neutropenia.
Lead Product(s): Paclitaxel,Encequidar,Dostarlimab
Therapeutic Area: Oncology Brand Name: Taxol
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Athenex
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Lead Product(s) : Paclitaxel,Encequidar,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Athenex
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Oral paclitaxel, relative to intravenous paclitaxel, was associated with less neuropathy and was not associated with an increase in febrile neutropenia.
Brand Name : Taxol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 20, 2022
Details:
OMS721 (narsoplimab) was not observed to shorten the time to recovery in critically ill patients with COVID-19 in this study. The study did not identify any new safety signals for narsoplimab in the setting of critically ill COVID-19 patients.
Lead Product(s): Narsoplimab
Therapeutic Area: Infections and Infectious Diseases Brand Name: OMS721
Study Phase: Phase IIIProduct Type: Large molecule
Recipient: Omeros
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Lead Product(s) : Narsoplimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Omeros
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OMS721 (narsoplimab) was not observed to shorten the time to recovery in critically ill patients with COVID-19 in this study. The study did not identify any new safety signals for narsoplimab in the setting of critically ill COVID-19 patients.
Brand Name : OMS721
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 15, 2022
Details:
OMS721 (narsoplimab) was selected for inclusion in the I-SPY COVID Trial because of its demonstrated ability to inhibit complement activation, inflammation, and coagulation, the three components that characterize COVID-19.
Lead Product(s): Narsoplimab
Therapeutic Area: Infections and Infectious Diseases Brand Name: OMS721
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Omeros
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Lead Product(s) : Narsoplimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Omeros
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OMS721 (narsoplimab) was selected for inclusion in the I-SPY COVID Trial because of its demonstrated ability to inhibit complement activation, inflammation, and coagulation, the three components that characterize COVID-19.
Brand Name : OMS721
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 15, 2022
Details:
The lead product candidate, evorpacept (ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain.
Lead Product(s): Evorpacept,Deruxtecan
Therapeutic Area: Oncology Brand Name: ALX148
Study Phase: IND EnablingProduct Type: Large molecule
Recipient: ALX Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Lead Product(s) : Evorpacept,Deruxtecan
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : ALX Oncology
Deal Size : Not Applicable
Deal Type : Not Applicable
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in ...
Details : The lead product candidate, evorpacept (ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain.
Brand Name : ALX148
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 15, 2022
Details:
To minimize potential toxicity a relatively low oral dose of 5 mg/kg/day for a duration of 5 days was selected to be administered to patients randomized into the CSA (cyclosporine) arm.
Lead Product(s): Cyclosporine,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Brand Name: CsA
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Lead Product(s) : Cyclosporine,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : To minimize potential toxicity a relatively low oral dose of 5 mg/kg/day for a duration of 5 days was selected to be administered to patients randomized into the CSA (cyclosporine) arm.
Brand Name : CsA
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 08, 2022
Details:
ARX788 is an anti-HER2 antibody drug conjugate (ADC), is a homogeneous and highly stable ADC that maximizes potential anti-tumor activity by optimizing the number and position of its payloads and the chemical bonds that conjugate the payloads to the antibody.
Lead Product(s): ARX788
Therapeutic Area: Oncology Brand Name: ARX788
Study Phase: Phase IIProduct Type: Large molecule
Recipient: Ambrx Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of ARX788...
Details : ARX788 is an anti-HER2 antibody drug conjugate (ADC), is a homogeneous and highly stable ADC that maximizes potential anti-tumor activity by optimizing the number and position of its payloads and the chemical bonds that conjugate the payloads to the anti...
Brand Name : ARX788
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 25, 2022
Details:
Aviptadil is a synthetic form of Human Vasoactive Intestinal Polypeptide and was selected because of the potential to reduce inflammation and stabilize the air sacs of hospitalized because of injury from acute respiratory distress syndrome, which is the major cause of death.
Lead Product(s): Aviptadil Acetate,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Zyesami
Study Phase: Phase IIProduct Type: Peptide
Sponsor: NRx Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Lead Product(s) : Aviptadil Acetate,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : NRx Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Aviptadil is a synthetic form of Human Vasoactive Intestinal Polypeptide and was selected because of the potential to reduce inflammation and stabilize the air sacs of hospitalized because of injury from acute respiratory distress syndrome, which is the ...
Brand Name : Zyesami
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 31, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?